A year af­ter cost cuts, Nanobi­otix has a deal with J&J to li­cense its lead ra­dioen­hancer prod­uct

Nanobi­otix and John­son & John­son have struck a li­cens­ing deal for the French biotech’s lead prod­uct, an ex­per­i­men­tal ther­a­py de­signed to boost the ef­fi­ca­cy of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER